Sunrise Oncology Partners
233 Spring Street
New York, NY 10013
P: (212) 123­1223
F: (212) 123­1224
Patient Nam e:  Mott, Elizabeth 
Patient Number: 12345678Date:  01/08/2019
Date Of Birth:   08/29/1960
Date Type Details Outcome Comment
5/1/2018 Other Therapies Synthroid 175 mcg tablet Active
5/1/2018 Other Therapies Zoloft 50 mg tablet Active
Allergies
No known allergies have been entered for this patient.
Medical and Surgical History
Hypothyroidism. Mild anxiety.
Date Type ICD­9 ICD­10 Problem Comment Status
Date Type Details Outcome Comment
9/18/2018 Surgery Tonsillectomy 1960s
Social History
Patient is married.  No history of tobacco use.  Mrs. Mott reports the following support system: lives with family. Her diet consists of regular 
meals. She indicates her daily activity level as: daily activities.
Alcohol
 Use 
Yes, Weekly.
Family History
Reviewed and unchanged.
Gyn History
Menarche at the age of 12. LMP more than 10 years ago.
Review
 Of S
ystems
Constitution al
 Symptoms: Patient reports:  mild fatigue,  no weakness,  no weight loss,  no fevers,  no chills, no diaphoresis,  no night 
sweat s , no hot 
flashes. exertional dyspnea, no cough
Eyes: Pat
ient offers no eye complaints. 
Gastrointestinal : Patient offers no gastrointestinal complaints.  no nausea,   no vomiting,  no dysphagia,  no  abdominal pain,  no diarrhea,  no 
const
ipation
Musculoskeletal: bone pain,  no back pain,  no arthralgia  
Integ
umentary: Patient reports: no rash, no pruritis, no skin lesions, no dry skin
Page 1 of 2  
FOLLOW UP VISIT
Chief Complaint
Mrs. Mott is a 58 year old woman who was diagnosed with breast c ancer in April 2018. She was found to have extensive 
bone metastases, adenopathy and hepatic lesions. Tumor  was biopsied showing E R positive, PR positive, Her2 amplified 
breast cancer. Started paclitaxel, tr astuzumab and pertuzumab 5/8/18. Added zolendronic acid. Completed six cycles  of TH 
and pertuzumab. P D on October 2018 scan. Switched to Tykerb and Xeloda. Here for follow up and to disc uss imaging 
results.
Ongoing Treatment  EventsNeurological: Patient reports: no headache, no peripheral neuropathy, no focal weakness, no tremor, no altered consciousness, n
oseizures, no speech impairment, no dizziness.  no paralysis,  nervousness,
Vital Signs
Vitals on 01/08/19 11:27:00 AM: Height=66in, Weight=155lb, Pulse=74, SystolicBP=122, DiastolicBP=68  
P
hysical 
General:  Patient appears:   well developed and well nourished,  No alopecia noted.  
Eyes: No scleral icterus, and/or pallor. Conjunctiva clear. EOMs intact. Pupils equal and reactive to light. 
Card
iovascular:  Heart  with regular rate and rhythm. Normal S1 and S2. S3, S4 No gallop. No rubs or clicks. No bruits. Pedal pulses  
present. 
Ch
est: Clear no rales/rhonchi. No dullness to percussion. No wheezing. Chest wall expansion normal. No chest wall tenderness. No  
stridor. 
Ab
domen: Soft. Non­tender. Non­distended. No palpable masses. No ascites. No hepatosplenomegaly. Bowel sounds present in all 
quadrant
s. No hernia. 
Hematologic/
L
ymphatic:  No cervical lymphadenopathy. No supraclavicular lymphadenopathy. No axillary lymphadenopathy. No inguinal  
lymphadenopathy. No petechiae. No ecchymosis. 
S
kin: No rashes. No lesions.  Extremities appear normal. No evidence of cyanosis.  No edema.  No clubbing present. 
Neurologic:  Alert and oriented.  Normal speech.  Cranial nerves in tact.  
Genitourinary:  E xamination deferred.  
Rectal: E xamination deferred.  
Gynecological:  Examination deferred.
Laboratory Results
Lab results on 01/08/2019: Sodium=135 mmol/L, Potassium= 4.2 mmol/L, CO2=31 mmol/L, Chloride=99 mmol/L, Glucose=84 mg/dL, 
Calcium=9.0 mg/dL, BUN=14 mg/dL, Creat=1.1 mg/dL, Alk Phos=45 U/L, ALT=21 U/L, AST=23 U/L, Total Bili=0.9 mg/dL, Albumin=3.7g 
dL, Total Protein=7.5 g/dL
. WBC=4.1 x10E3/uL, RBC=4.63 x10E6/uL, HGB=9.9 g/dL, HCT=31.4%, MCV=68 fL, MCH=21.4 pg, 
MCHC=31.5 g/dL, RDW=16.1 %, Plat=179 x10E3/uL, ANC=2.8 x10E3/uL
, Lymph#=1.0 x10E3/uL, MONO#=0.2  x10E3/uL, BASO#=0.1 
x10E3/uL, EOS#=0.1 x10E3/uL, MONO%=5 %, BASO%=1 %, EOS%=1 %, Neut%=68 %
I
maging Results
Radiology results were reviewed and discussed with the patient, including 4/2018- MRI Brain no metastasis deep white matter changes 
suggestive of inflammatory
 process. PET/CT - left breast mass; diffuse bone metastases; liver lesions suspicious for metastatic breast 
cancer.
Primary Dx 
198.5 - Secondary malignant neoplasm of bone and bone marrow, Diagnosed Apr 2018
174.9 - Malignant neoplasm of breast (female), unspecified site, Diagnosed Apr 2018
Assessment
S
tage 4  ER HER2 positive breast cancer with bone and liver metastases. Patient had a negative brain MRI.  Testing of tumor 
demonstrates ER+ PR+. HER2neu equivocal on IHC. FISH positive.
 Completed four cycles  of TH plus pertuzumab with response. CT 
CAP in July month showed interval decrease in size of liver lesions, stable bone metastases. However, scan performed in October  
showed progression with increased size of liver mets. Patient on lapatinib and capecitabine. Minimal side effects aside from moderate 
fatigue.
 Patient's disease has progressed per CT yesterday which unfortunately shows new liver, bone and likely lung metastases. 
Reco
mmendation/Plan
Time spent with patient was  35 minutes. Over half the time was spent counseling and coordinating care, which included the  
following:
Arranged patient treatment education.
Reviewed with patient  treatment side effects.
S
upportive measures reviewed.
All questions answered.
Page 2 of 2  Electronically signed:DATE Jan 08, 2019  
TIME 12:08PM  
Shannon Wu, M.D.
